GC Therapeutics Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • GC Therapeutics's estimated annual revenue is currently $7.4M per year.(i)
  • GC Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • GC Therapeutics has 48 Employees.(i)
  • GC Therapeutics grew their employee count by 37% last year.

GC Therapeutics's People

NameTitleEmail/Phone
1
CEO & Co-FounderReveal Email/Phone
2
Co-founder and Chief Scientific OfficerReveal Email/Phone
3
Scientific Co-Founder and Head Discovery PlatformsReveal Email/Phone
4
CFO ConsultantReveal Email/Phone
5
Head Translational and Regulatory StrategyReveal Email/Phone
6
Director OperationsReveal Email/Phone
7
Director Process DevelopmentReveal Email/Phone
8
Senior Operations ManagerReveal Email/Phone
9
Scientist IIIReveal Email/Phone
10
Scientist IIReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is GC Therapeutics?

GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church’s lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.

keywords:N/A

N/A

Total Funding

48

Number of Employees

$7.4M

Revenue (est)

37%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.4M48-17%$53M
#2
$4.7M48-38%$30M
#3
$5.6M48N/AN/A
#4
$6.5M48N/AN/A
#5
$5.4M489%N/A